FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3044430045> ?p ?o ?g. }

• W3044430045 endingPage "1781" @default.
• W3044430045 startingPage "1781" @default.
• W3044430045 abstract "Abstract Background: Macrophages(MΦs) are an abundant and important component of multiple myeloma (MM) microenvironment, and support the survival of MM cells and promote their resistance to chemotherapy. It has been proposed that MΦs have great plasticity and can differentiate into 2 major polarized states, M1 (“classically activated”) and M2 (“alternatively activated”). M1 macrophages are considered to be anti-tumoural and pro-inflammatory, whereas M2 macrophages are characterized by efficient activity of tumour promotion and suppression of adaptive immunity.IL-32, a novel proinflammatory cytokine, has been found to play a crucial role in a variety of inflammatory diseases and cancers. In this study, we investigated the immunomodulatory effects and underlying mechanisms of IL-32γ on macrophage polarization and MΦ-mediated drug resistance in myeloma cells. Results: First, we found that both bone marrow supernatant and peripheral blood supernatant of MM patients showed significantly higher levels of IL-32 as compared with those of healthy controls. We also detected IL-32 in MM cell lines and M-CSF-induced MOs by qRT-PCR and Western blot, which showed that IL-32 expression was higher in MM cell lines than in MOs. We next investigated the polarization profiles and functional activities of IL-32γ-treated MOs. After stimulated with recombinant IL-32γ,MOs exhibited upregulated expression of cell-surface molecules and cytokines associated with M2 polarization(CD206,Dectin-1, and IL-10), while M1-polarizing marker(CD86) were down-regulated. Further, Western blot was applied to detect the inflammation molecular pathway in MOs, which showed that IL-32γ treatment activated the JAK-STAT3 pathway and NF-κB pathway. This pro-M2MO polarization effect of IL-32γ was inhibited by the addition of specific inhibitors of STAT3 and NF-kB. Moreover, co-culture experiments revealed that IL-32γ-educated MOs provided a survival benefit to myeloma cells, as tested with several anti-myeloma agents including bortezomib and doxorubicin. The pro-survival effect was associated with less cleavage of caspase-3 and PARP in myeloma cells, and thus less apoptosis. The STAT3 and NF-κB inhibitors partially inhibited the observed IL-32γ-induced and MOs -mediated resistance to bortezomib in MM cells. Conclusions:IL-32γ could effectively induce the polarization of M2 MOs, leading to enhanced MO-mediated drug resistance in myeloma cells as the result of activating the JAK-STAT3 and NF-κB pathways in MOs. Disclosures No relevant conflicts of interest to declare." @default.
• W3044430045 created "2020-07-29" @default.
• W3044430045 creator A5006423482 @default.
• W3044430045 creator A5024244700 @default.
• W3044430045 creator A5030354203 @default.
• W3044430045 creator A5036246435 @default.
• W3044430045 creator A5047399826 @default.
• W3044430045 creator A5064842058 @default.
• W3044430045 creator A5071462292 @default.
• W3044430045 creator A5076516025 @default.
• W3044430045 creator A5079526895 @default.
• W3044430045 creator A5084566787 @default.
• W3044430045 creator A5089639451 @default.
• W3044430045 date "2017-12-07" @default.
• W3044430045 modified "2023-09-30" @default.
• W3044430045 title "IL-32γ Induces M2 Macrophage Polarization with Enhanced Ability of Macrophage-Mediated Drug Resistance in Myeloma Cells through STAT3 and NF-κB Activation" @default.
• W3044430045 doi "https://doi.org/10.1182/blood.v130.suppl_1.1781.1781" @default.
• W3044430045 hasPublicationYear "2017" @default.
• W3044430045 type Work @default.
• W3044430045 sameAs 3044430045 @default.
• W3044430045 citedByCount "0" @default.
• W3044430045 crossrefType "journal-article" @default.
• W3044430045 hasAuthorship W3044430045A5006423482 @default.
• W3044430045 hasAuthorship W3044430045A5024244700 @default.
• W3044430045 hasAuthorship W3044430045A5030354203 @default.
• W3044430045 hasAuthorship W3044430045A5036246435 @default.
• W3044430045 hasAuthorship W3044430045A5047399826 @default.
• W3044430045 hasAuthorship W3044430045A5064842058 @default.
• W3044430045 hasAuthorship W3044430045A5071462292 @default.
• W3044430045 hasAuthorship W3044430045A5076516025 @default.
• W3044430045 hasAuthorship W3044430045A5079526895 @default.
• W3044430045 hasAuthorship W3044430045A5084566787 @default.
• W3044430045 hasAuthorship W3044430045A5089639451 @default.
• W3044430045 hasConcept C104317684 @default.
• W3044430045 hasConcept C153911025 @default.
• W3044430045 hasConcept C164027704 @default.
• W3044430045 hasConcept C185592680 @default.
• W3044430045 hasConcept C202751555 @default.
• W3044430045 hasConcept C203014093 @default.
• W3044430045 hasConcept C2776090121 @default.
• W3044430045 hasConcept C2776415932 @default.
• W3044430045 hasConcept C2776682551 @default.
• W3044430045 hasConcept C2776914184 @default.
• W3044430045 hasConcept C2778690821 @default.
• W3044430045 hasConcept C2779244956 @default.
• W3044430045 hasConcept C2780007613 @default.
• W3044430045 hasConcept C2781101188 @default.
• W3044430045 hasConcept C2910375186 @default.
• W3044430045 hasConcept C502942594 @default.
• W3044430045 hasConcept C54355233 @default.
• W3044430045 hasConcept C55493867 @default.
• W3044430045 hasConcept C81885089 @default.
• W3044430045 hasConcept C86803240 @default.
• W3044430045 hasConcept C8891405 @default.
• W3044430045 hasConceptScore W3044430045C104317684 @default.
• W3044430045 hasConceptScore W3044430045C153911025 @default.
• W3044430045 hasConceptScore W3044430045C164027704 @default.
• W3044430045 hasConceptScore W3044430045C185592680 @default.
• W3044430045 hasConceptScore W3044430045C202751555 @default.
• W3044430045 hasConceptScore W3044430045C203014093 @default.
• W3044430045 hasConceptScore W3044430045C2776090121 @default.
• W3044430045 hasConceptScore W3044430045C2776415932 @default.
• W3044430045 hasConceptScore W3044430045C2776682551 @default.
• W3044430045 hasConceptScore W3044430045C2776914184 @default.
• W3044430045 hasConceptScore W3044430045C2778690821 @default.
• W3044430045 hasConceptScore W3044430045C2779244956 @default.
• W3044430045 hasConceptScore W3044430045C2780007613 @default.
• W3044430045 hasConceptScore W3044430045C2781101188 @default.
• W3044430045 hasConceptScore W3044430045C2910375186 @default.
• W3044430045 hasConceptScore W3044430045C502942594 @default.
• W3044430045 hasConceptScore W3044430045C54355233 @default.
• W3044430045 hasConceptScore W3044430045C55493867 @default.
• W3044430045 hasConceptScore W3044430045C81885089 @default.
• W3044430045 hasConceptScore W3044430045C86803240 @default.
• W3044430045 hasConceptScore W3044430045C8891405 @default.
• W3044430045 hasLocation W30444300451 @default.
• W3044430045 hasOpenAccess W3044430045 @default.
• W3044430045 hasPrimaryLocation W30444300451 @default.
• W3044430045 hasRelatedWork W1990884245 @default.
• W3044430045 hasRelatedWork W2000622288 @default.
• W3044430045 hasRelatedWork W2075470411 @default.
• W3044430045 hasRelatedWork W2078377719 @default.
• W3044430045 hasRelatedWork W2092409417 @default.
• W3044430045 hasRelatedWork W2160959184 @default.
• W3044430045 hasRelatedWork W2233124939 @default.
• W3044430045 hasRelatedWork W2476947275 @default.
• W3044430045 hasRelatedWork W2577535432 @default.
• W3044430045 hasRelatedWork W2586986177 @default.
• W3044430045 hasRelatedWork W2591376440 @default.
• W3044430045 hasRelatedWork W2736775973 @default.
• W3044430045 hasRelatedWork W2748596787 @default.
• W3044430045 hasRelatedWork W2786377846 @default.
• W3044430045 hasRelatedWork W2807028416 @default.
• W3044430045 hasRelatedWork W2884747526 @default.
• W3044430045 hasRelatedWork W2955687945 @default.
• W3044430045 hasRelatedWork W2969862706 @default.
• W3044430045 hasRelatedWork W3203891014 @default.
• W3044430045 hasRelatedWork W3213975580 @default.

• next